Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights the potential of nanotechnology-based formulations in hair care and treatment, emphasizing how these innovative materials can enhance the stability, efficacy, and safety of active compounds while addressing the limitations of conventional formulations.

This review examines new formulations for delivering 5-α-reductase inhibitors to improve targeted drug delivery in androgenetic alopecia, but reports no new clinical results.

This review discusses recent advances in hair follicle research, highlighting therapeutic and cosmetic applications, but reports no new study results.

This review summarizes current knowledge on the diagnosis and treatment of hirsutism but provides no new clinical results.

This chapter reviews patchy hair loss due to skin disease, nail disorders related to chronic trauma, and treatments for small carcinomas, but it reports no new clinical findings.

This review discusses strategies for managing dermatological symptoms of hyperandrogenism in PCOS by reducing androgen levels and actions, and reports no new clinical results.

This review highlights the potential of nanocarriers, like liposomes and solid lipid nanoparticles, in improving targeted drug delivery and effectiveness for androgenetic alopecia treatment, while noting the hurdles of clinical trials and regulatory approval for these advanced methods.

This review discusses the potential of nanocarriers like liposomes and nanoparticles to enhance the delivery and efficacy of treatments for androgenetic alopecia, while noting the challenges of clinical translation, such as securing reliable trials and regulatory approval.

This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.

This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.

This systematic review discusses various topical, oral, injectable, and non-pharmacological treatments for androgenetic alopecia, examining both current and emerging therapeutic options in addressing this common form of hair loss.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

Androgenetic alopecia treatments focus on reducing hair loss by targeting hormones, with new therapies showing promise but needing more research.

This study found that a novel topical dutasteride lotion, FOL100, demonstrated excellent safety, tolerability, and usability with promising signs of clinical benefit for mild-to-moderate male pattern baldness.

This review synthesizes recent advancements in clinical trichology, highlighting updates on androgenetic alopecia treatments like low-dose oral minoxidil, 5α-reductase inhibitors, and other therapeutic options for various alopecia types, including telogen/anagen effluvium and alopecia areata, and detailed approaches for scarring alopecias and pediatric trichology.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

This review highlights the potential of nanotechnology in enhancing the treatment of androgenetic alopecia by facilitating targeted drug delivery, improving drug stability, and increasing concentration at target sites, although clinical validation and scalable manufacturing are needed for practical implementation.

This article explores the role of ketoconazole shampoo in hair care beyond treating dandruff and seborrhoeic dermatitis, suggesting it may reduce hair shedding and chronic scalp inflammation, potentially complementing treatments for androgenetic alopecia.

This review compiled and evaluated numerous studies on alopecia treatments, highlighting promising pharmacological strategies like JAK inhibitors for alopecia areata and advancements in regenerative medicine for androgenetic alopecia, while also stressing the importance of personalized, mechanism-targeted approaches for improved outcomes across different alopecia subtypes.

This article discusses male androgenetic alopecia, describing its progression and pattern, and reports no new findings or clinical results.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

This review discusses the diagnosis and treatment options for androgenetic alopecia, including trichoscopy and therapies like minoxidil and hair transplantation, but reports no new clinical results.

This article reviews current diagnostic methods and treatments for hair loss, including FDA-approved drugs and surgical options, but reports no new research findings.

The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.

This study reports that incomplete information in a reverse supply chain can lead to efficiency losses, but a two-part tariff contract for the remanufacturer may improve performance by eliciting private information from collectors.

This article reviews various causes and treatments for hair loss and reports no new clinical findings; androgenetic alopecia and surgical options like hair transplantation are highlighted.

In this study, among 30 patients with androgenetic alopecia, topical Minoxidil was effective alone or in combination with either oral or microneedling-applied Dutasteride, with the microneedling approach offering promising results and fewer side effects compared to oral Dutasteride.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.